Literature DB >> 4086169

Effects of selected repeated intravitreal chemotherapeutic agents.

J Vernot, G A Peyman, R Gailitis, R Fiscella, M Woodhouse, D Weinberg.   

Abstract

The toxic effects of repeated intravitreal injections of selected chemotherapeutic agents were studied in female albino rabbits. Three groups of eyes participated in each therapeutic regimen. Agents studied were doxorubicin (dox), 3 and 5 micrograms; 5-fluorouracil (5-FU), 0.375 and 1.0 mg; bleomycin (bleo), 15 micrograms; thiotepa (thio), 12 micrograms; etoposide (VP-16), 150 micrograms; and methotrexate (MTX), 600 mic. Toxicity was evaluated using electroretinography (ERG) in 66% and histopathology in 100% of eyes 5 weeks following the initial injection and at least 2 weeks after the final injection of each series. Eyes receiving 2 doses of dox 3 micrograms showed no toxicity. Eyes receiving 3 or more doses of dox 3 micrograms and those treated with 2 or more doses of dox 5 demonstrated toxicity proportional to the number of doses received. Eyes treated with 5-FU 0.375 or 1.0 mg showed no toxic reaction. Successive intravitreal injections of 5-FU, 0.375 mg and dox 5 micrograms, and 5-FU, dox, and bleo produced no toxicity. Eyes treated with successive intravitreal injections of 5-FU, dox, bleo, and thio displayed decreased ERG response. The addition of VP-16 and MTX resulted in further loss of ERG response and more severe histologic retinal changes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4086169     DOI: 10.1007/BF00137646

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  17 in total

1.  5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite.

Authors:  M Blumenkranz; E Hernandez; A Ophir; E W Norton
Journal:  Ophthalmology       Date:  1984-02       Impact factor: 12.079

2.  Evaluation of toxicity of intravitreal antineoplastic drugs.

Authors:  G A Peyman; D Greenberg; G A Fishman; R Fiscella; A Thomas
Journal:  Ophthalmic Surg       Date:  1984-05

Review 3.  Eye toxicity of cancer chemotherapy: a review of the literature.

Authors:  J D Griffin; M B Garnick
Journal:  Cancer       Date:  1981-10-01       Impact factor: 6.860

Review 4.  Proliferative vitreoretinopathy and chemotherapeutic agents.

Authors:  G A Peyman; J Schulman
Journal:  Surv Ophthalmol       Date:  1985 May-Jun       Impact factor: 6.048

5.  Neuropathologic study on chronic neurotoxicity of 5-fluorouracil and its masked compounds in dogs.

Authors:  R Okeda; T Karakama; S Kimura; S Toizumi; T Mitsushima; Y Yokoyama
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

6.  Selection of therapeutic agents for intraocular proliferative disease. Cell culture evaluation.

Authors:  M S Blumenkranz; A Claflin; A S Hajek
Journal:  Arch Ophthalmol       Date:  1984-04

7.  Evaluation of intravitreal 5-fluorouracil, vincristine, VP 16, doxorubicin, and thiotepa in primate eyes.

Authors:  A Barrada; G A Peyman; J Case; G Fishman; A Thomas; R Fiscella
Journal:  Ophthalmic Surg       Date:  1984-09

8.  Inhibition of experimental intraocular proliferation with intravitreous 5-fluouracil. A transmission electron-microscopic study in rabbits.

Authors:  W Kulnig; S Binder; B Riss; C Skorpik
Journal:  Ophthalmologica       Date:  1984       Impact factor: 3.250

9.  Fluorouracil for the treatment of massive periretinal proliferation.

Authors:  M S Blumenkranz; A Ophir; A J Claflin; A Hajek
Journal:  Am J Ophthalmol       Date:  1982-10       Impact factor: 5.258

10.  Clearance of intravitreal 3H-fluorouracil.

Authors:  J L Case; G A Peyman; A Barrada; R Hendricks; R Fiscella; M Hindi
Journal:  Ophthalmic Surg       Date:  1985-06
View more
  1 in total

1.  Intravitreal injection of methotrexate in an experimental rabbit model: determination of ultrastructural changes.

Authors:  Ebru B Ozkan; Altan A Ozcan; Hande Taylan Sekeroglu; Yurdun Kuyucu; Hulya Ozgun; Sait Polat
Journal:  Indian J Ophthalmol       Date:  2013-07       Impact factor: 1.848

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.